( BRANFORD Conn.--(BUSINESS WIRE)--Jun 1...)Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting,Health

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 13, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 and Phase 2a clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, were presented in two sessions at the SLEEP 2007 Annual Meeting of the Associated Professional Sleep Societies (APSS) in Minneapolis, Minnesota. Two Phase 2b clinical studies with NG2-73 in chronic insomnia patients are currently being conducted by the Company. Data presented at the APSS meeting today includes the following:

"Effects of NG2-73 on Sleep Onset, Quality and Next Day Function in a Transient Insomnia Study" (Phase 2a)

NG2-73 is a partial agonist with preference for GABA(A) receptors containing the alpha-3 subunit. This mechanism of action may provide an important alternative to existing therapeutics for insomnia.

This double-blind, placebo-controlled, multi-center, randomized trial evaluated the efficacy of four dose groups of NG2-73 versus placebo in reducing Latency to Persistent Sleep (LPS) in healthy adults in a sleep laboratory, single-night, polysomnographic model of transient insomnia. This model of transient insomnia used both first night adaptation and "phase-advance" to create insomnia in healthy subjects. Subjects completed questionnaires assessing sleep effects, sleep quality, and next day functioning. Safety was monitored as per usual practice. Three hundred and sixty nine adults, aged 24 - 63, with no self-reported sleep disorders, were enrolled.

LPS was significantly reduced, compared to placebo, at all doses of NG2-73, in a dose-dependent manner with mean LPS of 30.8 minutes for the placebo group, and 17.8, 10.6, 7.8, and 6.6 minutes for the 1, 3, 10, and 20 mg NG2-73 groups, respectively. Subjective sleep latency (sSL) was significantly reduced compared to placebo at all doses. All four NG2-73 treatment groups reported that their sl
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results